Rheumatology
Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
Soo-Kyung Cho, Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Shin-Seok Lee, Hye-Soon Lee, Sung-Hoon Park, Yeon-Ah Lee, Min-Chan Park, Sung Hae Chang, Hyoun-Ah Kim, Seung-Ki Kwok, Hae-Rim Kim, Hyun-Sook Kim, Bo Young Yoon, Wan-Sik Uhm, Yong-Gil Kim, Jae Hoon Kim, Jisoo Lee, Jeongim Choi, Yoon-Kyoung Sung
Korean J Intern Med. 2023;38(4):546-556. Published online June 20, 2023
Background/Aims: We aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease- modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs.
Methods: A quasi-exper..
|
|
Gastroenterology
Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Korean J Intern Med. 2020;35(5):1104-1113. Published online April 21, 2020
Background/Aims: The optimal timing for initiation of anti-tumor necrosis factor (TNF) therapy in Crohn’s disease (CD) is still debated. Little is known about the clinical outcomes of early versus late administration of anti-TNF agents, especially in Asian CD patients. We aimed to evaluate the imp..
|
|
Rheumatology
Liver enzyme elevation in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors: a single-center historical cohort study
Su Jin Choi, Ji Seon Oh, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
Korean J Intern Med. 2020;35(3):723-731. Published online December 26, 2019
Background/Aims: Tumor necrosis factor inhibitors (TNFi) have been known to induce liver enzyme elevation, sometimes associated with viral reactivation or toxic hepatitis. We evaluated the incidence and risk factors of TNFi-associated liver enzyme elevation in Korean ankylosing spondylitis (AS) pati..
|
|
Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Yong-Beom Park, Sung-Hwan Park
Korean J Intern Med. 2019;34(3):669-677. Published online November 29, 2017
Background/Aims: Inhibition of tumor necrosis factor (TNF) is an effective treatment for rheumatoid arthritis (RA), but safety concerns about malignancy remain. The aim of this study was to evaluate cancer risk in RA patients treated with TNF inhibitors (TNFi), based on Korean Nationwide Health Insu..
|
|
Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases
Junhee Pyo, Soo-Kyung Cho, Dam Kim, Yoon-Kyoung Sung
Korean J Intern Med. 2018;33(6):1241-1251. Published online December 28, 2017
Background/Aims: To estimate the level of agreement and positivity rates of latent tuberculosis infection (LTBI) tests prior to the use of tumor necrosis factor (TNF) inhibitors in relation to underlying rheumatic diseases and endemic tuberculosis levels.
Methods: The Ovid-Medline, Embase, and Coch..
|
|
Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis
Young Mo Kang, Young-Eun Park, Won Park, Jung-Yoon Choe, Chul-Soo Cho, Seung-Cheol Shim, Sang Cheol Bae, Chang-Hee Suh, Hoon-Suk Cha, Eun Mi Koh, Yeong-Wook Song, Bin Yoo, Shin-Seok Lee, Min-Chan Park, Sang-Heon Lee, Catherine Arendt, Willem Koetse, Soo-Kon Lee
Korean J Intern Med. 2018;33(6):1224-1233. Published online January 5, 2018
Background/Aims: The objective of this study was to determine the efficacy and safety of add-on therapy with certolizumab pegol (CZP) in active rheumatoid arthritis (RA) patients of a single ethnicity.
Methods: In this 24-week, phase 3, randomized, double-blind, placebo-controlled trial, eligible p..
|
|
Gastroenterology
Association of a genetic polymorphism of IL1RN with risk of acute pancreatitis in a Korean ethnic group
Jin Woo Park, Ja Sung Choi, Ki Joon Han, Sang Heun Lee, Eui Joo Kim, Jae Hee Cho
Korean J Intern Med. 2018;33(6):1103-1110. Published online November 10, 2017
Background/Aims: Several epidemiological studies have validated the association of interleukin gene polymorphisms with acute pancreatitis (AP) in different populations. However, there have been few studies in Asian ethnic groups. We aimed to investigate the relationships between inflammatory cytoki..
|
|
Rheumatology
Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Soyoung Won, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Dae-Hyun Yoo, Sang-Cheol Bae
Korean J Intern Med. 2018;33(5):1016-1024. Published online March 13, 2017
Background/Aims: To evaluate the impact of isoniazid (INH) treatment for latent tuberculosis infection (LTBI) on the development of liver function test (LFT) abnormality and the persistence of tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients.
Methods: We retrospectively ..
|
|
Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
Hyemin Jeong, Yeong Hee Eun, In Young Kim, Hyungjin Kim, Joong Kyong Ahn, Jaejoon Lee, Eun-Mi Koh, Hoon-Suk Cha
Korean J Intern Med. 2018;33(2):407-416. Published online October 12, 2016
Background/Aims: To evaluate drug survival of the tumor necrosis factor α inhibitors (TNFi) and risk factors for the drug discontinuation in patients with ankylosing spondylitis (AS).
Methods: We retrospectively evaluated 487 AS patients at a single tertiary hospital. Among the TNFi users, drug s..
|
|
Gastroenterology
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
Korean J Intern Med. 2018;33(1):1-19. Published online December 8, 2017
Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. In particular, gastrointestinal involvement in BD i..
|
|
Nephrology
Tumor necrosis factor α is a risk factor for infection in peritoneal dialysis patients
Eunjung Kang, Seihran Kim, Hwa Jung Lee, Inhwee Park, Heungsoo Kim, Gyu-Tae Shin
Korean J Intern Med. 2016;31(4):722-729. Published online March 22, 2016
Background/Aims: It has been shown that circulating tumor necrosis factor α (TNF-α) is elevated in end stage renal disease patients; however, the relationship between TNF-α and the development of infection in these patients is unknown. In this study, we investigated the association of plasma TNF-..
|
|
Endocrinology-metabolism
Adipokines, insulin-like growth factor binding protein-3 levels, and insulin sensitivity in women with polycystic ovary syndrome
Hyejin Lee, Jee-Young Oh, Yeon-Ah Sung
Korean J Intern Med. 2013;28(4):456-463. Published online July 1, 2013
Background/AimsMany women with polycystic ovary syndrome (PCOS) exhibit insulin resistance. Adipose tissue plays an important role in insulin resistance, and adipokines including tumor necrosis factor (TNF)-α and adiponectin are altered in PCOS. Insulin-like growth factor bin..
|
|
Pulmonology
Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor
Keun Bum Chung, Eun Young Lee, Jong Pil Im, Sung Koo Han, Jae-Joon Yim
Korean J Intern Med. 2013;28(2):174-179. Published online February 27, 2013
Background/AimsIndividuals being treated with tumor necrosis factor (TNF)-α inhibitors are at increased risk of developing tuberculosis (TB). We determined the clinical characteristics and treatment response of patients who developed TB after using TNF-α inhibitors. ..
|
|
A Case of Tuberculous Arthritis Following the Use of Etanercept
Seung Won Choi, Jong Joon Ahn, Young Tae Hwang, Sang Hoon Koh, Sung Do Cho
Korean J Intern Med. 2009;24(4):397-401. Published online November 27, 2009
Etanercept is a tumor necrosis factor (TNF) inhibitor that has been used for the treatment of chronic inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Because of its immunosuppressive activity, opportunistic infections have been noted in treate..
|
|
Effects of TNF-α and Leptin on Weight Loss in Patients with Stable Chronic Obstructive Pulmonary Disease
Kyeong-Cheol Shin, Jin Hong Chung, Kwan Ho Lee
Korean J Intern Med. 2007;22(4):249-255. Published online December 20, 2007
BackgroundWeight loss is common in patients with chronic obstructive pulmonary disease (COPD). However, the mechanisms of this weight loss are still unclear. MethodsSixty male patients with stable COPD and 45 healthy male cont..
|
|
Adenoviral Pneumonia During Etanercept Treatment in a Patient with Rheumatoid Arthritis
Min-Jung Kang, Myung-Sin Kim, Eun-Hwa Choi, Kyoung-Eun Lee, You-Kyoung Kim, Hee-Jung Choi
Korean J Intern Med. 2007;22(1):63-66. Published online March 31, 2007
Inhibitors of tumor necrosis factor-alpha (TNF-α) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infect..
|
|
Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
Jung Hoon Lee, Tae Nyeun Kim, Sun Taek Choi, Byung Ik Jang, Kyeong-Cheol Shin, Sam Beom Lee, Young Ran Shim
Korean J Intern Med. 2007;22(1):24-27. Published online March 31, 2007
Behçet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had ..
|
|
|